Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Nivolumab |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | no benefit |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | lung non-small cell carcinoma | no benefit | Nivolumab | Phase III | Actionable | In a Phase III trial, treatment with Opdivo (nivolumab) did not result in longer median progression-free survival (PFS) or overall survival (OS) than chemotherapy treatment in patients with stage IV or recurrent non-small cell lung cancer with PD-L1 (CD274) expression of greater than 5%, resulting in a median PFS of 4.2 mo vs. 5.9 mo with chemotherapy (HR=1.15; 95% CI 0.91-1.45; p=0.25) and a median OS of 14.4 mo vs. 13.2 mo with chemotherapy (HR=1.15; 95% CI 0.80-1.30) (PMID: 28636851; NCT02041533). | 28636851 |
PubMed Id | Reference Title | Details |
---|---|---|
(28636851) | First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. | Full reference... |